Background: Guidelines recommend that patients with heart failure with reduced ejection
fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as …

BACKGROUND: Heart failure (HF) with preserved ejection fraction (EF) accounts for a
substantial proportion of cases of HF, and to date no treatments have clearly improved …

Background—Heart failure with preserved ejection fraction (EF) is a common syndrome, but
trends in treatments and outcomes are lacking. Methods and Results—We analyzed data …

Despite significant advances in therapies for patients with heart failure with reduced ejection
fraction (HFrEF), there are no evidence-based therapies for heart failure with preserved …

Background—Heart failure (HF) can occur in patients with preserved (HFpEF, EF≥ 50%) or
reduced (HFrEF, EF< 50%) ejection fraction (EF), but changes in EF after HF diagnosis are …

Background—Left ventricular remodeling, as commonly measured by left ventricular ejection
fraction (LVEF), is associated with clinical outcomes. Although change in LVEF over time …

Heart failure (HF) with reduced ejection fraction (HFrEF) is a common and costly condition
that diminishes patients' health status and confers a poor prognosis. Despite the availability …

Recent epidemiological studies have demonstrated that nearly half of all patients with heart
failure (HF) have preserved left ventricular ejection fraction (HFPEF). Compared to those …

Aims Heart failure (HF) is a major public health burden worldwide. Of patients presenting
with HF, 30–55% have a preserved ejection fraction (HFPEF) rather than a reduced ejection …

Aims To identify variables predicting ejection fraction (EF) recovery and characterize
prognosis of heart failure (HF) patients with EF recovery (HFrecEF). Methods and results …